Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Patent Challenge Mechanism For FOBs Should Be Scrapped, FTC Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Report views early patent resolution as unnecessary and potentially harmful to patent incentives and consumers.

You may also be interested in...



Follow-On Biologics “Integrally Related” To Patent Reform Bill, Sen. Hatch Says

Remarks suggest the potential for an alternate vehicle for addressing brand firms’ concerns about patent certainty, even as work on overall health care reform intensifies.

Follow-On Biologics “Integrally Related” To Patent Reform Bill, Sen. Hatch Says

Remarks suggest the potential for an alternate vehicle for addressing brand firms’ concerns about patent certainty, even as work on overall health care reform intensifies.

FTC’s Low Blow On FOBs

FTC concludes that extended brand exclusivity – or any generic exclusivity – is unnecessary for a robust follow-on biologics market.

Related Content

Topics

UsernamePublicRestriction

Register

LL111109

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel